{Reference Type}: Journal Article
{Title}: A Case of Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency.
{Author}: Tamura H;Nakashima K;Uchiyama N;Ogawa S;Hatada H;Yoshida N;Uchida K;Ozono Y;Tanaka H;Yamamto K;Kawakami H;
{Journal}: Intern Med
{Volume}: 0
{Issue}: 0
{Year}: Nov 2021 6
{Factor}: 1.282
{DOI}: 10.2169/internalmedicine.8254-21
{Abstract}: Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been shown to be useful in treating either advanced or recurrent KRAS/NRAS/BRAF wild-type colorectal cancer. We herein report the case of a 60-year-old man with short bowel syndrome who developed hematochezia due to panitumumab-induced colitis with vitamin K deficiency during third-line chemotherapy. The cause of vitamin K deficiency was the lack of intravenous vitamin K supplementation following a change from central venous nutrition to peripheral venous nutrition. We advise clinicians to carefully check for colitis and manage the infusions of chemotherapy patients with short bowel syndrome.